Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) Stock Competitors & Peer Comparison

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, SGMART.NS has a market cap of 103.4B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while SGMART.NS trades at ₹811.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas SGMART.NS's P/E ratio is 78.65. In terms of profitability, SAROJA.NS's ROE is N/A, compared to SGMART.NS's ROE of +0.08%. Regarding short-term risk, SAROJA.NS is less volatile compared to SGMART.NS. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check SGMART.NS's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, SGMART.BO has a market cap of 103.3B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while SGMART.BO trades at ₹812.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas SGMART.BO's P/E ratio is 78.64. In terms of profitability, SAROJA.NS's ROE is N/A, compared to SGMART.BO's ROE of +0.08%. Regarding short-term risk, SAROJA.NS is less volatile compared to SGMART.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check SGMART.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, TCC.BO has a market cap of 12B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while TCC.BO trades at ₹240.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas TCC.BO's P/E ratio is 31.53. In terms of profitability, SAROJA.NS's ROE is N/A, compared to TCC.BO's ROE of +0.06%. Regarding short-term risk, SAROJA.NS is less volatile compared to TCC.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check TCC.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, PRIZOR.NS has a market cap of 10.4B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while PRIZOR.NS trades at ₹1,020.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas PRIZOR.NS's P/E ratio is 87.78. In terms of profitability, SAROJA.NS's ROE is N/A, compared to PRIZOR.NS's ROE of N/A. Regarding short-term risk, SAROJA.NS is less volatile compared to PRIZOR.NS. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check PRIZOR.NS's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, YSL.BO has a market cap of 9.2B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while YSL.BO trades at ₹29,865.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas YSL.BO's P/E ratio is 15.26. In terms of profitability, SAROJA.NS's ROE is N/A, compared to YSL.BO's ROE of +0.07%. Regarding short-term risk, SAROJA.NS is more volatile compared to YSL.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check YSL.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, HEXATRADEX.NS has a market cap of 8.7B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while HEXATRADEX.NS trades at ₹157.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas HEXATRADEX.NS's P/E ratio is -100.02. In terms of profitability, SAROJA.NS's ROE is N/A, compared to HEXATRADEX.NS's ROE of -0.00%. Regarding short-term risk, SAROJA.NS is less volatile compared to HEXATRADEX.NS. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check HEXATRADEX.NS's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, HEXATRADEX.BO has a market cap of 8.5B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while HEXATRADEX.BO trades at ₹155.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas HEXATRADEX.BO's P/E ratio is -98.23. In terms of profitability, SAROJA.NS's ROE is N/A, compared to HEXATRADEX.BO's ROE of -0.00%. Regarding short-term risk, SAROJA.NS is more volatile compared to HEXATRADEX.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check HEXATRADEX.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, MERCURYEV.BO has a market cap of 7.5B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while MERCURYEV.BO trades at ₹39.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas MERCURYEV.BO's P/E ratio is 425.11. In terms of profitability, SAROJA.NS's ROE is N/A, compared to MERCURYEV.BO's ROE of +0.02%. Regarding short-term risk, SAROJA.NS is less volatile compared to MERCURYEV.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check MERCURYEV.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, AERPACE.BO has a market cap of 5.2B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while AERPACE.BO trades at ₹34.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas AERPACE.BO's P/E ratio is -32.78. In terms of profitability, SAROJA.NS's ROE is N/A, compared to AERPACE.BO's ROE of -0.42%. Regarding short-term risk, SAROJA.NS is less volatile compared to AERPACE.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check AERPACE.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, VERITAS.BO has a market cap of 4.5B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while VERITAS.BO trades at ₹164.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas VERITAS.BO's P/E ratio is 4.07. In terms of profitability, SAROJA.NS's ROE is N/A, compared to VERITAS.BO's ROE of -0.00%. Regarding short-term risk, SAROJA.NS is less volatile compared to VERITAS.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check VERITAS.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, EUROASIA.BO has a market cap of 4.2B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while EUROASIA.BO trades at ₹306.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas EUROASIA.BO's P/E ratio is N/A. In terms of profitability, SAROJA.NS's ROE is N/A, compared to EUROASIA.BO's ROE of N/A. Regarding short-term risk, SAROJA.NS is more volatile compared to EUROASIA.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check EUROASIA.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, ANLON.NS has a market cap of 4.2B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while ANLON.NS trades at ₹665.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas ANLON.NS's P/E ratio is 63.45. In terms of profitability, SAROJA.NS's ROE is N/A, compared to ANLON.NS's ROE of N/A. Regarding short-term risk, SAROJA.NS is less volatile compared to ANLON.NS. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check ANLON.NS's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, SWISSMLTRY.BO has a market cap of 4.1B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while SWISSMLTRY.BO trades at ₹17.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas SWISSMLTRY.BO's P/E ratio is 66.60. In terms of profitability, SAROJA.NS's ROE is N/A, compared to SWISSMLTRY.BO's ROE of +0.05%. Regarding short-term risk, SAROJA.NS is less volatile compared to SWISSMLTRY.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check SWISSMLTRY.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, CROPSTER.BO has a market cap of 4B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while CROPSTER.BO trades at ₹4.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas CROPSTER.BO's P/E ratio is 2.46. In terms of profitability, SAROJA.NS's ROE is N/A, compared to CROPSTER.BO's ROE of +0.13%. Regarding short-term risk, SAROJA.NS is less volatile compared to CROPSTER.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check CROPSTER.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, MARBLE.BO has a market cap of 3B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while MARBLE.BO trades at ₹118.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas MARBLE.BO's P/E ratio is 42.19. In terms of profitability, SAROJA.NS's ROE is N/A, compared to MARBLE.BO's ROE of +0.11%. Regarding short-term risk, SAROJA.NS is less volatile compared to MARBLE.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check MARBLE.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, SILKFLEX.NS has a market cap of 2.4B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while SILKFLEX.NS trades at ₹220.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas SILKFLEX.NS's P/E ratio is 32.46. In terms of profitability, SAROJA.NS's ROE is N/A, compared to SILKFLEX.NS's ROE of N/A. Regarding short-term risk, SAROJA.NS is more volatile compared to SILKFLEX.NS. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check SILKFLEX.NS's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, SICAGEN.BO has a market cap of 2.2B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while SICAGEN.BO trades at ₹53.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas SICAGEN.BO's P/E ratio is 20.22. In terms of profitability, SAROJA.NS's ROE is N/A, compared to SICAGEN.BO's ROE of +0.04%. Regarding short-term risk, SAROJA.NS is less volatile compared to SICAGEN.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check SICAGEN.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, SICAGEN.NS has a market cap of 2.2B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while SICAGEN.NS trades at ₹53.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas SICAGEN.NS's P/E ratio is 19.13. In terms of profitability, SAROJA.NS's ROE is N/A, compared to SICAGEN.NS's ROE of +0.04%. Regarding short-term risk, SAROJA.NS is less volatile compared to SICAGEN.NS. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check SICAGEN.NS's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, MAXIMUS.BO has a market cap of 2B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while MAXIMUS.BO trades at ₹14.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas MAXIMUS.BO's P/E ratio is 25.24. In terms of profitability, SAROJA.NS's ROE is N/A, compared to MAXIMUS.BO's ROE of +0.11%. Regarding short-term risk, SAROJA.NS is less volatile compared to MAXIMUS.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check MAXIMUS.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, DHOOTIN.BO has a market cap of 1.8B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while DHOOTIN.BO trades at ₹285.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas DHOOTIN.BO's P/E ratio is 10.24. In terms of profitability, SAROJA.NS's ROE is N/A, compared to DHOOTIN.BO's ROE of +0.12%. Regarding short-term risk, SAROJA.NS is less volatile compared to DHOOTIN.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check DHOOTIN.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, METROGLOBL.BO has a market cap of 1.8B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while METROGLOBL.BO trades at ₹143.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas METROGLOBL.BO's P/E ratio is 18.45. In terms of profitability, SAROJA.NS's ROE is N/A, compared to METROGLOBL.BO's ROE of +0.05%. Regarding short-term risk, SAROJA.NS is less volatile compared to METROGLOBL.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check METROGLOBL.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, MENAMANI.BO has a market cap of 1.7B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while MENAMANI.BO trades at ₹15.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas MENAMANI.BO's P/E ratio is 17913.58. In terms of profitability, SAROJA.NS's ROE is N/A, compared to MENAMANI.BO's ROE of +0.37%. Regarding short-term risk, SAROJA.NS is less volatile compared to MENAMANI.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check MENAMANI.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, DENEERS.NS has a market cap of 1.5B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while DENEERS.NS trades at ₹173.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas DENEERS.NS's P/E ratio is 9.28. In terms of profitability, SAROJA.NS's ROE is N/A, compared to DENEERS.NS's ROE of N/A. Regarding short-term risk, SAROJA.NS is less volatile compared to DENEERS.NS. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check DENEERS.NS's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, VISAMAN.NS has a market cap of 1.4B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while VISAMAN.NS trades at ₹97.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas VISAMAN.NS's P/E ratio is 61.60. In terms of profitability, SAROJA.NS's ROE is N/A, compared to VISAMAN.NS's ROE of N/A. Regarding short-term risk, SAROJA.NS is more volatile compared to VISAMAN.NS. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check VISAMAN.NS's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, CHANDRIMA.BO has a market cap of 1.3B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while CHANDRIMA.BO trades at ₹7.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas CHANDRIMA.BO's P/E ratio is 110.00. In terms of profitability, SAROJA.NS's ROE is N/A, compared to CHANDRIMA.BO's ROE of +0.02%. Regarding short-term risk, SAROJA.NS is less volatile compared to CHANDRIMA.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check CHANDRIMA.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, BNL.BO has a market cap of 1.2B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while BNL.BO trades at ₹118.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas BNL.BO's P/E ratio is 30.44. In terms of profitability, SAROJA.NS's ROE is N/A, compared to BNL.BO's ROE of +0.08%. Regarding short-term risk, SAROJA.NS is more volatile compared to BNL.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check BNL.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, ROCKINGDCE.NS has a market cap of 1.2B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while ROCKINGDCE.NS trades at ₹224.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas ROCKINGDCE.NS's P/E ratio is 24.99. In terms of profitability, SAROJA.NS's ROE is N/A, compared to ROCKINGDCE.NS's ROE of N/A. Regarding short-term risk, SAROJA.NS is less volatile compared to ROCKINGDCE.NS. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check ROCKINGDCE.NS's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, MYSORPETRO.BO has a market cap of 1.1B. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while MYSORPETRO.BO trades at ₹154.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas MYSORPETRO.BO's P/E ratio is -3307.00. In terms of profitability, SAROJA.NS's ROE is N/A, compared to MYSORPETRO.BO's ROE of +0.05%. Regarding short-term risk, SAROJA.NS is less volatile compared to MYSORPETRO.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check MYSORPETRO.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, OPTIFIN.BO has a market cap of 944.5M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while OPTIFIN.BO trades at ₹12.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas OPTIFIN.BO's P/E ratio is 16.21. In terms of profitability, SAROJA.NS's ROE is N/A, compared to OPTIFIN.BO's ROE of +0.07%. Regarding short-term risk, SAROJA.NS is less volatile compared to OPTIFIN.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check OPTIFIN.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, SANINFRA.BO has a market cap of 798.9M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while SANINFRA.BO trades at ₹50.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas SANINFRA.BO's P/E ratio is 45.96. In terms of profitability, SAROJA.NS's ROE is N/A, compared to SANINFRA.BO's ROE of +0.08%. Regarding short-term risk, SAROJA.NS is less volatile compared to SANINFRA.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check SANINFRA.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, GEL.BO has a market cap of 672.9M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while GEL.BO trades at ₹25.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas GEL.BO's P/E ratio is 303.33. In terms of profitability, SAROJA.NS's ROE is N/A, compared to GEL.BO's ROE of +0.02%. Regarding short-term risk, SAROJA.NS is less volatile compared to GEL.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check GEL.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, MRCAGRO.BO has a market cap of 665.8M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while MRCAGRO.BO trades at ₹30.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas MRCAGRO.BO's P/E ratio is 79.08. In terms of profitability, SAROJA.NS's ROE is N/A, compared to MRCAGRO.BO's ROE of +0.04%. Regarding short-term risk, SAROJA.NS is less volatile compared to MRCAGRO.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check MRCAGRO.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, MISHKA.BO has a market cap of 648.7M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while MISHKA.BO trades at ₹44.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas MISHKA.BO's P/E ratio is 1496.33. In terms of profitability, SAROJA.NS's ROE is N/A, compared to MISHKA.BO's ROE of +0.08%. Regarding short-term risk, SAROJA.NS is less volatile compared to MISHKA.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check MISHKA.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, KTIL.BO has a market cap of 633.7M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while KTIL.BO trades at ₹58.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas KTIL.BO's P/E ratio is 2.44. In terms of profitability, SAROJA.NS's ROE is N/A, compared to KTIL.BO's ROE of +1.84%. Regarding short-term risk, SAROJA.NS is less volatile compared to KTIL.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check KTIL.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, HRYNSHP.BO has a market cap of 612.4M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while HRYNSHP.BO trades at ₹103.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas HRYNSHP.BO's P/E ratio is 155.16. In terms of profitability, SAROJA.NS's ROE is N/A, compared to HRYNSHP.BO's ROE of +0.03%. Regarding short-term risk, SAROJA.NS is less volatile compared to HRYNSHP.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check HRYNSHP.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, VEL.BO has a market cap of 582.7M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while VEL.BO trades at ₹70.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas VEL.BO's P/E ratio is -13.02. In terms of profitability, SAROJA.NS's ROE is N/A, compared to VEL.BO's ROE of -0.32%. Regarding short-term risk, SAROJA.NS is less volatile compared to VEL.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check VEL.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, CONSTRONIC.BO has a market cap of 576.3M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while CONSTRONIC.BO trades at ₹46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas CONSTRONIC.BO's P/E ratio is 698.13. In terms of profitability, SAROJA.NS's ROE is N/A, compared to CONSTRONIC.BO's ROE of +0.06%. Regarding short-term risk, SAROJA.NS is less volatile compared to CONSTRONIC.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check CONSTRONIC.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, SEML.BO has a market cap of 555.5M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while SEML.BO trades at ₹35.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas SEML.BO's P/E ratio is 4.48. In terms of profitability, SAROJA.NS's ROE is N/A, compared to SEML.BO's ROE of +0.10%. Regarding short-term risk, SAROJA.NS is less volatile compared to SEML.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check SEML.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, CCAL.BO has a market cap of 546.4M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while CCAL.BO trades at ₹34.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas CCAL.BO's P/E ratio is -13.90. In terms of profitability, SAROJA.NS's ROE is N/A, compared to CCAL.BO's ROE of N/A. Regarding short-term risk, SAROJA.NS is more volatile compared to CCAL.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check CCAL.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, PANTH.BO has a market cap of 544.5M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while PANTH.BO trades at ₹9.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas PANTH.BO's P/E ratio is 1.40. In terms of profitability, SAROJA.NS's ROE is N/A, compared to PANTH.BO's ROE of +0.73%. Regarding short-term risk, SAROJA.NS is less volatile compared to PANTH.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check PANTH.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, IFL.BO has a market cap of 423.3M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while IFL.BO trades at ₹0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas IFL.BO's P/E ratio is -11.33. In terms of profitability, SAROJA.NS's ROE is N/A, compared to IFL.BO's ROE of -0.03%. Regarding short-term risk, SAROJA.NS is less volatile compared to IFL.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check IFL.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, TAVERNIER.BO has a market cap of 415.9M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while TAVERNIER.BO trades at ₹69.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas TAVERNIER.BO's P/E ratio is 11.99. In terms of profitability, SAROJA.NS's ROE is N/A, compared to TAVERNIER.BO's ROE of +0.12%. Regarding short-term risk, SAROJA.NS is less volatile compared to TAVERNIER.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check TAVERNIER.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, ACEMEN.BO has a market cap of 379M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while ACEMEN.BO trades at ₹120.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas ACEMEN.BO's P/E ratio is 518.26. In terms of profitability, SAROJA.NS's ROE is N/A, compared to ACEMEN.BO's ROE of +0.01%. Regarding short-term risk, SAROJA.NS is less volatile compared to ACEMEN.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check ACEMEN.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, RONI.BO has a market cap of 370.4M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while RONI.BO trades at ₹38.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas RONI.BO's P/E ratio is -73.25. In terms of profitability, SAROJA.NS's ROE is N/A, compared to RONI.BO's ROE of -0.03%. Regarding short-term risk, SAROJA.NS is less volatile compared to RONI.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check RONI.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, CHANDNIMACH.BO has a market cap of 335.2M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while CHANDNIMACH.BO trades at ₹98.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas CHANDNIMACH.BO's P/E ratio is 16.46. In terms of profitability, SAROJA.NS's ROE is N/A, compared to CHANDNIMACH.BO's ROE of +0.02%. Regarding short-term risk, SAROJA.NS is less volatile compared to CHANDNIMACH.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check CHANDNIMACH.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, AGARWALFT.NS has a market cap of 314.6M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while AGARWALFT.NS trades at ₹36.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas AGARWALFT.NS's P/E ratio is 8.68. In terms of profitability, SAROJA.NS's ROE is N/A, compared to AGARWALFT.NS's ROE of N/A. Regarding short-term risk, SAROJA.NS is more volatile compared to AGARWALFT.NS. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check AGARWALFT.NS's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, AAPLUSTRAD.BO has a market cap of 299.2M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while AAPLUSTRAD.BO trades at ₹1.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas AAPLUSTRAD.BO's P/E ratio is 61.50. In terms of profitability, SAROJA.NS's ROE is N/A, compared to AAPLUSTRAD.BO's ROE of +0.03%. Regarding short-term risk, SAROJA.NS is more volatile compared to AAPLUSTRAD.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check AAPLUSTRAD.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, AKG.NS has a market cap of 285.7M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while AKG.NS trades at ₹8.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas AKG.NS's P/E ratio is 83.59. In terms of profitability, SAROJA.NS's ROE is N/A, compared to AKG.NS's ROE of +0.01%. Regarding short-term risk, SAROJA.NS is less volatile compared to AKG.NS. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check AKG.NS's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, YASHINNO.BO has a market cap of 274.2M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while YASHINNO.BO trades at ₹40.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas YASHINNO.BO's P/E ratio is -35.21. In terms of profitability, SAROJA.NS's ROE is N/A, compared to YASHINNO.BO's ROE of -0.39%. Regarding short-term risk, SAROJA.NS is less volatile compared to YASHINNO.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check YASHINNO.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, DRL.BO has a market cap of 260.2M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while DRL.BO trades at ₹37.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas DRL.BO's P/E ratio is -889.25. In terms of profitability, SAROJA.NS's ROE is N/A, compared to DRL.BO's ROE of -0.00%. Regarding short-term risk, SAROJA.NS is less volatile compared to DRL.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check DRL.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, NEERAJ.BO has a market cap of 208.1M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while NEERAJ.BO trades at ₹18.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas NEERAJ.BO's P/E ratio is 40.26. In terms of profitability, SAROJA.NS's ROE is N/A, compared to NEERAJ.BO's ROE of +0.02%. Regarding short-term risk, SAROJA.NS is more volatile compared to NEERAJ.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check NEERAJ.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, TTIL.BO has a market cap of 208M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while TTIL.BO trades at ₹8.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas TTIL.BO's P/E ratio is 7.15. In terms of profitability, SAROJA.NS's ROE is N/A, compared to TTIL.BO's ROE of +0.05%. Regarding short-term risk, SAROJA.NS is less volatile compared to TTIL.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check TTIL.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, OPCHAINS.BO has a market cap of 203.8M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while OPCHAINS.BO trades at ₹29.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas OPCHAINS.BO's P/E ratio is 19.70. In terms of profitability, SAROJA.NS's ROE is N/A, compared to OPCHAINS.BO's ROE of +0.03%. Regarding short-term risk, SAROJA.NS is more volatile compared to OPCHAINS.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check OPCHAINS.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, PRADHIN.BO has a market cap of 203M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while PRADHIN.BO trades at ₹0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas PRADHIN.BO's P/E ratio is -3.96. In terms of profitability, SAROJA.NS's ROE is N/A, compared to PRADHIN.BO's ROE of +0.09%. Regarding short-term risk, SAROJA.NS is less volatile compared to PRADHIN.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check PRADHIN.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, ASPIRE.NS has a market cap of 201.1M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while ASPIRE.NS trades at ₹13.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas ASPIRE.NS's P/E ratio is 5.24. In terms of profitability, SAROJA.NS's ROE is N/A, compared to ASPIRE.NS's ROE of N/A. Regarding short-term risk, SAROJA.NS is less volatile compared to ASPIRE.NS. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check ASPIRE.NS's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, RAMAPETRO.BO has a market cap of 200M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while RAMAPETRO.BO trades at ₹12.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas RAMAPETRO.BO's P/E ratio is -2.14. In terms of profitability, SAROJA.NS's ROE is N/A, compared to RAMAPETRO.BO's ROE of +0.11%. Regarding short-term risk, SAROJA.NS is less volatile compared to RAMAPETRO.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check RAMAPETRO.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, SAENTER.BO has a market cap of 195.8M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while SAENTER.BO trades at ₹48.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas SAENTER.BO's P/E ratio is -12.06. In terms of profitability, SAROJA.NS's ROE is N/A, compared to SAENTER.BO's ROE of -0.05%. Regarding short-term risk, SAROJA.NS is more volatile compared to SAENTER.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check SAENTER.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, ALCHCORP.BO has a market cap of 173M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while ALCHCORP.BO trades at ₹35.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas ALCHCORP.BO's P/E ratio is -185.32. In terms of profitability, SAROJA.NS's ROE is N/A, compared to ALCHCORP.BO's ROE of -0.02%. Regarding short-term risk, SAROJA.NS is more volatile compared to ALCHCORP.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check ALCHCORP.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, FRONTCORP.BO has a market cap of 167.5M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while FRONTCORP.BO trades at ₹33.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas FRONTCORP.BO's P/E ratio is -20.41. In terms of profitability, SAROJA.NS's ROE is N/A, compared to FRONTCORP.BO's ROE of +0.15%. Regarding short-term risk, SAROJA.NS is less volatile compared to FRONTCORP.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check FRONTCORP.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, TAIIND.BO has a market cap of 145.8M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while TAIIND.BO trades at ₹25.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas TAIIND.BO's P/E ratio is 151.88. In terms of profitability, SAROJA.NS's ROE is N/A, compared to TAIIND.BO's ROE of -0.01%. Regarding short-term risk, SAROJA.NS is less volatile compared to TAIIND.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check TAIIND.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, SANBLUE.BO has a market cap of 140M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while SANBLUE.BO trades at ₹26.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas SANBLUE.BO's P/E ratio is 133.33. In terms of profitability, SAROJA.NS's ROE is N/A, compared to SANBLUE.BO's ROE of +0.01%. Regarding short-term risk, SAROJA.NS is more volatile compared to SANBLUE.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check SANBLUE.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, MULLER.BO has a market cap of 137.1M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while MULLER.BO trades at ₹209.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas MULLER.BO's P/E ratio is -264.28. In terms of profitability, SAROJA.NS's ROE is N/A, compared to MULLER.BO's ROE of +0.36%. Regarding short-term risk, SAROJA.NS is less volatile compared to MULLER.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check MULLER.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, PANKAJPIYUS.BO has a market cap of 113.8M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while PANKAJPIYUS.BO trades at ₹284.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas PANKAJPIYUS.BO's P/E ratio is 21.26. In terms of profitability, SAROJA.NS's ROE is N/A, compared to PANKAJPIYUS.BO's ROE of -0.00%. Regarding short-term risk, SAROJA.NS is less volatile compared to PANKAJPIYUS.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check PANKAJPIYUS.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, COMPUPN.BO has a market cap of 101.4M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while COMPUPN.BO trades at ₹3.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas COMPUPN.BO's P/E ratio is 1265.92. In terms of profitability, SAROJA.NS's ROE is N/A, compared to COMPUPN.BO's ROE of +0.00%. Regarding short-term risk, SAROJA.NS is less volatile compared to COMPUPN.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check COMPUPN.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, PARKERAC.BO has a market cap of 89.2M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while PARKERAC.BO trades at ₹17.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas PARKERAC.BO's P/E ratio is 10.37. In terms of profitability, SAROJA.NS's ROE is N/A, compared to PARKERAC.BO's ROE of +0.27%. Regarding short-term risk, SAROJA.NS is more volatile compared to PARKERAC.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check PARKERAC.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, SRUSTEELS.BO has a market cap of 88.7M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while SRUSTEELS.BO trades at ₹1.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas SRUSTEELS.BO's P/E ratio is 4.48. In terms of profitability, SAROJA.NS's ROE is N/A, compared to SRUSTEELS.BO's ROE of +0.03%. Regarding short-term risk, SAROJA.NS is less volatile compared to SRUSTEELS.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check SRUSTEELS.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, DEVINE.BO has a market cap of 81.5M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while DEVINE.BO trades at ₹8.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas DEVINE.BO's P/E ratio is 285.00. In terms of profitability, SAROJA.NS's ROE is N/A, compared to DEVINE.BO's ROE of +0.01%. Regarding short-term risk, SAROJA.NS is more volatile compared to DEVINE.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check DEVINE.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, FRASER.BO has a market cap of 77.1M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while FRASER.BO trades at ₹9.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas FRASER.BO's P/E ratio is -8.11. In terms of profitability, SAROJA.NS's ROE is N/A, compared to FRASER.BO's ROE of -0.12%. Regarding short-term risk, SAROJA.NS is less volatile compared to FRASER.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check FRASER.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, ROJL.BO has a market cap of 75.2M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while ROJL.BO trades at ₹1.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas ROJL.BO's P/E ratio is -49.67. In terms of profitability, SAROJA.NS's ROE is N/A, compared to ROJL.BO's ROE of +0.00%. Regarding short-term risk, SAROJA.NS is more volatile compared to ROJL.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check ROJL.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, IGCIL.BO has a market cap of 70.1M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while IGCIL.BO trades at ₹2.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas IGCIL.BO's P/E ratio is -2.40. In terms of profitability, SAROJA.NS's ROE is N/A, compared to IGCIL.BO's ROE of -0.47%. Regarding short-term risk, SAROJA.NS is less volatile compared to IGCIL.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check IGCIL.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, GANONPRO.BO has a market cap of 69M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while GANONPRO.BO trades at ₹7.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas GANONPRO.BO's P/E ratio is 13.20. In terms of profitability, SAROJA.NS's ROE is N/A, compared to GANONPRO.BO's ROE of +0.05%. Regarding short-term risk, SAROJA.NS is less volatile compared to GANONPRO.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check GANONPRO.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, REETECH.BO has a market cap of 63.4M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while REETECH.BO trades at ₹16.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas REETECH.BO's P/E ratio is 15.46. In terms of profitability, SAROJA.NS's ROE is N/A, compared to REETECH.BO's ROE of +0.03%. Regarding short-term risk, SAROJA.NS is more volatile compared to REETECH.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check REETECH.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, WWALUM.BO has a market cap of 62.3M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while WWALUM.BO trades at ₹18.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas WWALUM.BO's P/E ratio is -76.32. In terms of profitability, SAROJA.NS's ROE is N/A, compared to WWALUM.BO's ROE of +0.01%. Regarding short-term risk, SAROJA.NS is more volatile compared to WWALUM.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check WWALUM.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, ENTRINT.BO has a market cap of 60.3M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while ENTRINT.BO trades at ₹19.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas ENTRINT.BO's P/E ratio is -403.80. In terms of profitability, SAROJA.NS's ROE is N/A, compared to ENTRINT.BO's ROE of +0.04%. Regarding short-term risk, SAROJA.NS is more volatile compared to ENTRINT.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check ENTRINT.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, TRIVENIENT.BO has a market cap of 57.2M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while TRIVENIENT.BO trades at ₹1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas TRIVENIENT.BO's P/E ratio is 50.00. In terms of profitability, SAROJA.NS's ROE is N/A, compared to TRIVENIENT.BO's ROE of +0.01%. Regarding short-term risk, SAROJA.NS is more volatile compared to TRIVENIENT.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check TRIVENIENT.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, PADMAIND.BO has a market cap of 56M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while PADMAIND.BO trades at ₹8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas PADMAIND.BO's P/E ratio is 23.64. In terms of profitability, SAROJA.NS's ROE is N/A, compared to PADMAIND.BO's ROE of -7.60%. Regarding short-term risk, SAROJA.NS is less volatile compared to PADMAIND.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check PADMAIND.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, AMITINT.BO has a market cap of 54.8M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while AMITINT.BO trades at ₹3.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas AMITINT.BO's P/E ratio is 115.60. In terms of profitability, SAROJA.NS's ROE is N/A, compared to AMITINT.BO's ROE of -0.01%. Regarding short-term risk, SAROJA.NS is more volatile compared to AMITINT.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check AMITINT.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, ASHAI.BO has a market cap of 53.1M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while ASHAI.BO trades at ₹11.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas ASHAI.BO's P/E ratio is 62.38. In terms of profitability, SAROJA.NS's ROE is N/A, compared to ASHAI.BO's ROE of +0.02%. Regarding short-term risk, SAROJA.NS is more volatile compared to ASHAI.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check ASHAI.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, SAICOM.BO has a market cap of 50M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while SAICOM.BO trades at ₹0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas SAICOM.BO's P/E ratio is 21.05. In terms of profitability, SAROJA.NS's ROE is N/A, compared to SAICOM.BO's ROE of -0.00%. Regarding short-term risk, SAROJA.NS is less volatile compared to SAICOM.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check SAICOM.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, UTLINDS.BO has a market cap of 49.4M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while UTLINDS.BO trades at ₹1.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas UTLINDS.BO's P/E ratio is 75.00. In terms of profitability, SAROJA.NS's ROE is N/A, compared to UTLINDS.BO's ROE of -0.02%. Regarding short-term risk, SAROJA.NS is less volatile compared to UTLINDS.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check UTLINDS.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, DITCO.BO has a market cap of 42.8M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while DITCO.BO trades at ₹12.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas DITCO.BO's P/E ratio is 41.33. In terms of profitability, SAROJA.NS's ROE is N/A, compared to DITCO.BO's ROE of +0.01%. Regarding short-term risk, SAROJA.NS is less volatile compared to DITCO.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check DITCO.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, TSPIRITUAL.BO has a market cap of 37.2M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while TSPIRITUAL.BO trades at ₹1.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas TSPIRITUAL.BO's P/E ratio is -109.41. In terms of profitability, SAROJA.NS's ROE is N/A, compared to TSPIRITUAL.BO's ROE of -0.12%. Regarding short-term risk, SAROJA.NS is less volatile compared to TSPIRITUAL.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check TSPIRITUAL.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, WOMENNET.BO has a market cap of 37.1M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while WOMENNET.BO trades at ₹8.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas WOMENNET.BO's P/E ratio is 841.90. In terms of profitability, SAROJA.NS's ROE is N/A, compared to WOMENNET.BO's ROE of -0.07%. Regarding short-term risk, SAROJA.NS is more volatile compared to WOMENNET.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check WOMENNET.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, NAKSH.BO has a market cap of 36.9M. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while NAKSH.BO trades at ₹3.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas NAKSH.BO's P/E ratio is -9.92. In terms of profitability, SAROJA.NS's ROE is N/A, compared to NAKSH.BO's ROE of -0.07%. Regarding short-term risk, SAROJA.NS is less volatile compared to NAKSH.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check NAKSH.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, TINEAGRO.BO has a market cap of 0. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while TINEAGRO.BO trades at ₹32.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas TINEAGRO.BO's P/E ratio is N/A. In terms of profitability, SAROJA.NS's ROE is N/A, compared to TINEAGRO.BO's ROE of N/A. Regarding short-term risk, SAROJA.NS is more volatile compared to TINEAGRO.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check TINEAGRO.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, TERRAFORM.BO has a market cap of 0. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while TERRAFORM.BO trades at ₹7.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas TERRAFORM.BO's P/E ratio is N/A. In terms of profitability, SAROJA.NS's ROE is N/A, compared to TERRAFORM.BO's ROE of +0.00%. Regarding short-term risk, SAROJA.NS is more volatile compared to TERRAFORM.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check TERRAFORM.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, GDTRAGN.BO has a market cap of 0. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while GDTRAGN.BO trades at ₹21.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas GDTRAGN.BO's P/E ratio is N/A. In terms of profitability, SAROJA.NS's ROE is N/A, compared to GDTRAGN.BO's ROE of N/A. Regarding short-term risk, SAROJA.NS is more volatile compared to GDTRAGN.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check GDTRAGN.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, SHIVKAMAL.BO has a market cap of 0. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while SHIVKAMAL.BO trades at ₹10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas SHIVKAMAL.BO's P/E ratio is N/A. In terms of profitability, SAROJA.NS's ROE is N/A, compared to SHIVKAMAL.BO's ROE of N/A. Regarding short-term risk, SAROJA.NS is more volatile compared to SHIVKAMAL.BO. This indicates higher risk in terms of short-term price fluctuations for SAROJA.NS.Check SHIVKAMAL.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, SURANATP.BO has a market cap of 0. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while SURANATP.BO trades at N/A.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas SURANATP.BO's P/E ratio is N/A. In terms of profitability, SAROJA.NS's ROE is N/A, compared to SURANATP.BO's ROE of +0.15%. Regarding short-term risk, SAROJA.NS is not fully comparable compared to SURANATP.BO. This indicates unavailable risk data in terms of short-term price fluctuations for SAROJA.NS.Check SURANATP.BO's competition here

Saroja Pharma Industries India Ltd. (NSE: SAROJA.NS) plays a significant role within the Industrials sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SAROJA.NS stands at 138.3M. In comparison, JRELTD.BO has a market cap of 0. Regarding current trading prices, SAROJA.NS is priced at ₹36.10 on the NSE, while JRELTD.BO trades at ₹452.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SAROJA.NS currently has a P/E ratio of 13.39, whereas JRELTD.BO's P/E ratio is N/A. In terms of profitability, SAROJA.NS's ROE is N/A, compared to JRELTD.BO's ROE of -0.11%. Regarding short-term risk, SAROJA.NS is less volatile compared to JRELTD.BO. This indicates lower risk in terms of short-term price fluctuations for SAROJA.NS.Check JRELTD.BO's competition here